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In the report, we describe the first case of laparoscopic ovarian transposition prior to pelvic radio-chemo therapy in
a young female patient with advanced rectal cancer in Japan. A 14-year-old female visited a hospital because of
consistent diarrhea and melena. Colonoscopy examination showed a bulky tumor of the rectum, which was
diagnosed as moderately to poorly differentiated adenocarcinoma. The diagnosis was cT3N2aM1a (due to lymph
node in pelvic side wall), cStage IVA. In an attempt to improve local control and sphincter preservation, neoadjuvant
concurrent radio-chemo therapy was planned. Considering that pelvic irradiation particularly in young female might
cause ovarian failure, laparoscopic ovarian transposition was carried out prior to pelvic irradiation. Sequentially the
patient underwent low anterior resection of the rectum and lymphadenectomy including pelvic side wall. The
menstruation was maintained with delay for 6 months after adjuvant chemotherapy. There is no evidence of
cancer recurrence at 3 years after the surgery.
In premenopausal patients with rectal cancer undergoing pelvic irradiation, laparoscopic ovarian transposition is one of
the choices to prevent ovarian failure.
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As survival rates of colorectal cancer (CRC) improve
and more women delay their childbearing years until
their 3rd decade, it is evident that preserving fertility in
these patients is becoming increasingly important [1–4].
Ovarian transposition (OT), also known as oophoropexy,
is a surgical procedure that relocates the ovaries out of
the radiation field. First described in 1958, it was initially
performed at laparotomy in a uterine cervical cancer
patient to preserve ovarian function [5]. Here, we report
a case of rectal cancer in a young female patient, in
whom laparoscopic ovarian transposition (L-OT) prior
to neoadjuvant radio-chemo therapy was carried out to
prevent ovarian failure.* Correspondence: miyamamo@jcom.home.ne.jp
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A 14-year-old female visited a local hospital because of
persistent diarrhea and blood in her stool. Colonoscopy
showed a bulky tumor in the lower rectum (Figs. 1
and 2). The distance between the anal verge and the
lower edge of the tumor was 3 cm. The biopsy specimen
revealed moderately to poorly differentiated adenocarcin-
oma. The patient was referred to the National Cancer
Center Hospital. There was no remarkable medical history
in her past, no malignancy in her close relatives. Carbohy-
drate antigen 19–9 level rose up to 551 U/ml (<37), while
the carcinoembryonic antigen was 2.4 ng/ml (<5.0). The
rest laboratory examinations were within the normal
range. Magnetic resonance imaging revealed the tumor of
the rectum, 76 mm in diameter (Fig. 3), and detected sev-
eral swelling lymph nodes in mesorectum and left pelvic
side wall, which were rational for diagnosing as metastasis
(Fig. 4). The clinical diagnosis was cT3N2aM1a (due to
lymph node metastasis in pelvic side wall), cStage
IVA according to the TNM classification (the 7th edition).
In an attempt to improve local control and sphincters distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 The colonoscopy revealed a Type 2 lesion. The anal margin of
the tumor was below the middle transverse rectal fold
Fig. 3 MRI of sagittal plane revealed a balky tumor in lower rectum,
measured 76 mm in diameter
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apy was planned. Considering that pelvic irradiation
particularly in young female might cause ovarian failure,
the patient underwent L-OT before the pelvic irradiation
to prevent direct radiation injury to the ovaries.
The procedures were carried out under general
anesthesia. A 12-mm port was inserted supra-umbilicus
using open technique. After insufflation of abdominal
cavity, two 5 mm ports were inserted under direct vision
into both sides of hypogastric area. The patient was
placed in Trendelenburg’s position to free the pelvis and
enable visualization of the genital tract. Small amount of
ascites was collected for cytology, and it revealed nega-
tive for cancer cell. The right mesocolon and the meso-
sigmoid to the mesorectum in the left were separatedFig. 2 The colonoscopy showed a long cancer canalfrom the underlying retroperitoneum to expose the ovar-
ian vessels and ureters. Stapler was used to divide the
utero-ovarian ligament, and the ovarian vessels were
mobilized carefully (Fig. 5). The ovary was transposed to
the level of the anterior superior iliac spine, anterior to
the psoas muscle, and anchored to the peritoneum. Clips
were placed to ensure visualization on plain abdominalFig. 4 The lymph node in the left pelvic wall was swelling and positive
for contrast enhancement
Fig. 5 Utero-ovarian ligament was transected the adnexa of uterus
by stapling device
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25 min, and the loss of blood was less than 10 ml.
A total of 50.4 Gy given in 28 fractions was delivered
to the pelvis (Fig. 8), with concurrent biweekly fluoro-
uracil and oxaliplatin. The patient had a partial response
to neoadjuvant radio-chemo therapy, and carbohydrate
antigen 19–9 level decreased to 34 U/ml (<37). The dis-
tance between the anal verge and the lower edge of the
tumor decreased to 2 cm after neoadjuvant radio-chemo
therapy. Total mesorectal excision, lymphadenectomy ofFig. 6 Postoperative roentgenogram showing the position of metallic
clips applied to each ovarypelvic side wall, and diverting ileostomy were performed
after 7 weeks from the completion of neoadjuvant therapy
(Fig. 9). The postoperative course was uneventful. Histo-
logical examination of the resected specimen revealed
moderately to poorly differentiated adenocarcinoma in-
cluding mucinous component. Infiltration of vessels and
nerves was also observed. Final diagnosis was pT3N1bM0,
pStage IIIB. The tumor regression was grade 2, according
to the definition by the American Joint Committee on
Cancer. The patient received eight courses of FOLFOX as
adjuvant chemotherapy and underwent stoma closure.
She experienced a return of menses with 6 months dur-
ation after adjuvant chemotherapy. She has now been
followed up for 3 years after surgery with no evidence of
tumor recurrence.
Discussion
We have reported the case of young female, who main-
tained menstrual cycles following a multidisciplinary
therapy for advanced rectal cancer including L-OT prior
to concurrent pelvic irradiation and chemotherapy. Re-
cent analyses have indicated that the incidence of CRC
in women younger than the age of 40 years was 3–6 %
and keep increasing in the western countries [6]. In
Japan, CRC is now the second most commonly diagnosed
cancer and the most leading cause of cancer-related
deaths for women according to the cancer statistics
released by Center for Cancer Control and Information
Services, Japan [7, 8].
Our case was sporadic early-onset without an apparent
predisposing condition for CRC. Sporadic early-onset
CRC frequently displays adverse histologic features, such
as signet ring cell and mucinous differentiations, and
perineural and venous invasion. Probably because of
these features, they tend to have a poorer outcome than
adult population [9, 10]. As a result of its rarity, there
has been no prospective study, targeting young CRC pa-
tients, including children. Therefore, the therapeutic
strategy for young CRC patients is primarily extrapolated
from adult trials. Neoadjuvant radio-chemo therapy is
getting to be used in lower rectal cancer to reduce local
recurrence and attempt sphincter preservation [11, 12].
As survival rates of CRC improve and more women
delay their childbearing years until their 3rd decade, it is
evident that preserving fertility in these patients is be-
coming increasingly important [1–4]. A retrospective
study in women, aged 40 years and younger with CRC,
has reported that the incidence of amenorrhea in colon
and rectal cancer patients were 4.2 % (3 of 72) and 94.1 %
(48 of 51), respectively [13]. This data strongly supports
that irradiation to the pelvis causes severe damage to the
ovaries, and young female patients, who are scheduled to
undergo pelvic irradiation, should be counseled regarding
fertility preservation options. However, physicians tend to
Fig. 7 CT showed the ovaries transposed to the level of the anterior superior iliac spine, anterior to the psoas muscle
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and standard complications of radio-chemo therapy. They
are not likely to address fertility concerns with their pa-
tients before cancer treatment. Unfortunately, only 15 %
of women aged 18–45 years with CRC received pretreat-
ment fertility counseling and nearly 40 % of the women
had documented difficulty with pregnancy or changes in
menses after treatment [14].
In our multidisciplinary team conference including
pediatric oncologists and radiologists, ovarian failure
due to pelvic irradiation was concerned. The patient of
our case was 14 years old and still in the age of puberty.
Gonadal hormones from ovaries were supposed to have
important roles not only in fertility but also in physical
growth. Many procedures that previously required a
laparotomy are now done by laparoscopy. L-OT has
been established as a simple and reliable method withFig. 8 The clips attached to the ovaries (yellow arrow) were relocated
outside of the radiation fieldreduced morbidity with Hodgkin’s disease and cervical
cancer patients [15]. However, there are no studies in
CRC patients that address the effects of OT, on female
fertility at present. In spite of many cases of OT in the
other cancer patients, very limited cases of OT in rectal
cancer patients have been reported by a literature search
of PubMed by cross-referencing the terms “ovarian
transposition” and “rectal cancer.” There are only 31
cases, including our case, that underwent OT in CRC
(Table 1) [16–24]. All the cases had chosen laparoscopic
approach. The patients’ ages ranged from 14 to 38. Most
of them had been diagnosed as T3 and N1 in TNM clas-
sification. The case of T1bN0M0, reported by Tulandi
[16], was an exceptional case that “transanal resection”
had been performed for cT1 lesion initially, and it re-
vealed pT1b. Instead of an additional lymphadenectomy,
irradiation was held.
Several factors have been identified as significant de-
terminants of ovarian failure. Age at the time of irradi-
ation is known to be an important factor determiningFig. 9 The resected specimen of total mesorectal excision. The tumor
shrank and turned to be a depressed scar
Table 1 Summary of reported cases of ovarian transposition for rectal cancer
Author-year Age TNM (stage) Total dose Chemotherapy Menstruation (follow-up period) Pregnancy
Tulandi 1998 [16] 34 T1bN0M0 45Gy/25fr No + +a
Bisharah 2003 [17] 28 NA 45Gy/25fr No +
Farber 2005 [18] 28 T4aN0M0 45Gy/25fr 5-FU + LV +
Kurt 2007 [19] 24 T3N1M0 45Gy/25fr 5-FU + LV +b +c
Elizur 2009 [20] 28 T3N1M0 NA No NA




Al-Badawi 2010 [21] 23 T3N1M0 NA No Lost (10 months)
23 TXN1M0 No + (60 months)
26 T3N1M0 No + (46 months)
28 T3N1M0 No Lost (12 months)
Gareer 2011 [22] 15 +
17 +
(Needle oophoropexy) 19 +
20 + 3 of 10 achieved pregnancy






Al-Asari 2012 [23] 21 Two of three maintained
their menstruatione
21-27 NA NA NA
27




Present case 14 pT3N1bM0 50.4Gy/28fr 5-FU + OX + (24 months)
aTwo years after surgery [33]
bEight weeks after the completion of the CRT
cIn utero exitus
dDelivered a child 2 years after her operation
eOne of them resumed menstruation with 4 months delay, resumed menstruation with 6 months delay
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in patients who are less than 40 years of age [25]. Lower
and increasingly fractionated doses raise the possibility
of repair of the damaged follicular population [26]. Per-
manent ovarian failure occurs on exposure of 20 Gy of
pelvic irradiation in women less than 40 years [27]. The
gonadal vascular damage among the procedures and the
distance of the transposed ovaries from the radiation
field are also very important [28, 29].
OT is not always enough to achieve fertility preserva-
tion. Five patients out of 31, in previous rectal cancercases underwent L-OT, had experienced menopause
after pelvic irradiation. It also threatens the other geni-
tals in pelvis. The human oocyte is very sensitive to radi-
ation, with an estimated median lethal dose of less than
2 Gy [30]. The estimated dose of radiation at which half
of the follicles are lost in humans is 4 Gy [31]. Exposure
to the uterus must be considered in fertility as well;
exposure of the prepubertal uterus to doses between 14
and 30 Gy are likely to result in poor uterine growth and
uterine dysfunction [32]. There are few literatures about
endometrial activity after pelvic irradiation, but as a
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destroy the normal endometrium [33]. We have laid
much emphasis on preservation of ovarian function, and
radiation field including the uterus was planned to
improve curability for cancer in this case. Preserving
fallopian tubes is technically complex so that they have
been resected through the procedure dividing adnexa
of the uterus. When the patient desires to have a
child, in-vitro fertilization must be considered. Instead
of these damages in genitals, it is surprising that six
patients out of 31 cases had been pregnant.
Chemotherapy constitutes a significant cytotoxic risk
to the ovaries; it can also result in premature ovarian
failure. Additionally, 5-FU has almost no effect on human
reproductive function, but oxaliplatin induces cellular
apoptosis. It therefore has moderate gonadotoxic effects
and can cause ovarian failure and birth defects [34]. The
clinical diagnosis of the patient was cT3N2aM1a (due to
lymph node metastasis in pelvic side wall), cStage IVA.
Oxaliplatin was added to the treatment regimen because it
may improve disease-free survival in patients with ad-
vanced CRC [35–37]. However, it goes without saying that
radiation plus oxaliplatin may cause severe or complete
ovarian failure. We believed that the risk and degree of
ovarian failure might be decreased by performing OT.
Conclusions
In conclusion, L-OT is one of the choices to prevent
ovarian failure and infertility in premenopausal patients
of rectal cancer, who are scheduled to undergo pelvic
irradiation. Further well-designed studies regarding this
issue are warranted.
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